Cargando…

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial

PURPOSE: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD). METHODS: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heier, Jeffrey S., Ho, Allen C., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Brown, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Manuscripts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954160/ https://www.ncbi.nlm.nih.gov/pubmed/37008402 http://dx.doi.org/10.1177/24741264221126061

Ejemplares similares

INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial
por: Brown, David M., et al.
Publicado: (2022)

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME
por: Avery, Robert L., et al.
Publicado: (2023)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
por: Terasaki, Hiroko, et al.
Publicado: (2019)

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
por: Brown, David M., et al.
Publicado: (2021)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Result of intravitreal aflibercept injection for myopic choroidal neovascularization
por: Chen, Shih-Lin, et al.
Publicado: (2021)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

Intravitreal aflibercept treatment for choroidal neovascularization secondary to laser pointer
por: Keles, Ali, et al.
Publicado: (2020)

Systemic counterregulatory response of angiopoietin‐2 after aflibercept therapy for nAMD: a potential escape mechanism
por: Angermann, Reinhard, et al.
Publicado: (2020)

Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases
por: Kaiser, Peter K, et al.
Publicado: (2019)

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks
por: Esen, Ebru, et al.
Publicado: (2015)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
por: Korol, Andrii R, et al.
Publicado: (2017)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Cytokine Profiles and the Effect of Intravitreal Aflibercept Treatment on Experimental Choroidal Neovascularization
por: Wang, Chen, et al.
Publicado: (2020)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
por: Makri, Olga E, et al.
Publicado: (2018)

Intravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients with Neovascular Age-Related Macular Degeneration: Outcomes of the SIGHT Study
por: Li, Xiaoxin, et al.
Publicado: (2017)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum]
Publicado: (2017)

Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
por: Inatani, Masaru, et al.
Publicado: (2020)

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial
por: Mitchell, Paul, et al.
Publicado: (2021)

Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept
por: Wiciński, Michał, et al.
Publicado: (2021)

Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
por: Korol, Andrii R, et al.
Publicado: (2016)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

A customized regimen of intravitreal aflibercept for the treatment of choroidal neovascularization secondary to different chorioretinal diseases
por: Moussa, Magdy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9qvi7fluius2qtm2t4qqipvh58